By Fineline Cube 
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received approval from Japan’s Ministry of Health, Labour and Welfare for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. This marks a significant expansion of Dupixent’s therapeutic applications in the Japanese market.
Drug Profile
Dupixent, an interleukin-4 (IL-4) receptor alpha antagonist, is already approved in Japan for several conditions, including atopic dermatitis, asthma, chronic sinusitis with nasal polyps (CRSwNP), nodular prurigo, and chronic spontaneous urticaria (CSU). The latest approval extends its use to COPD patients who require additional therapeutic options.
Clinical Trial Results
The approval is supported by positive results from the Phase III BOREAS study, which demonstrated that Dupixent significantly reduced exacerbations and improved lung function compared to placebo, highlighting its potential to address unmet medical needs in COPD patients.-Fineline Info & Tech